Tel Aviv University scientists have made progress in developing a treatment using the NAP peptide to counter Alzheimer’s and other neurological conditions (see here previously). Their new compound dramatically decreased the excessive buildup of the protein tau, which misfolds in … Continue reading →

Israel’s NeoTX Therapeutics (see here Mar 2020) has had FDA approval to begin Phase 2a human trials of its Naptumomab Estafenatox (NAP) treatment for non-small cell lung cancer. NAP binds bacteria to the tumor while activating tumor specific immune cells. … Continue reading →

In her lab, Professor Illana Gozes of Tel Aviv University (reported here previously) repaired live but damaged brain cells taken from deceased Alzheimer’s patients and an autistic child. It showed that her experimental NAP peptide could be used to treat … Continue reading →

Tel Aviv University Professor Illana Gozes has made yet another discovery (see previous) about the gene fragment NAP and its potential to treat Alzheimer’s and other brain diseases. NAP stops abnormal Tau proteins from tangling the microtubules that maintain the … Continue reading →

(Thanks to NoCamels.com) Professor Illana Gozes of Tel Aviv University has created a new peptide (short protein) called NAP that latest trials indicate could treat neuro-degenerative diseases such as Alzheimer’s, ALS or Parkinson’s. http://nocamels.com/2013/07/new-study-may-may-help-lead-the-way-to-treatment-for-neurodegenerative-diseases/